| scholarly article | Q13442814 |
| P2093 | author name string | Wei Qiao | |
| Nitin Jain | |||
| Michael J Keating | |||
| William G Wierda | |||
| Michael H Kroll | |||
| Shuju Feng | |||
| Qi Wu | |||
| Xuelin Huang | |||
| Varsha Gandhi | |||
| Prithviraj Bose | |||
| Lisa S Chen | |||
| Philip A Thompson | |||
| Yongying Jiang | |||
| Nichole D Cruz | |||
| P2860 | cites work | Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain | Q24321955 |
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group | Q31097476 | ||
| Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. | Q52592631 | ||
| Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. | Q52723842 | ||
| Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. | Q52993622 | ||
| Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. | Q53963822 | ||
| Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies. | Q54122926 | ||
| Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. | Q54316160 | ||
| Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. | Q54328623 | ||
| Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. | Q55004285 | ||
| Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. | Q55069337 | ||
| Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib | Q63408235 | ||
| The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia | Q81531944 | ||
| Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG) | Q89454352 | ||
| Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib | Q89777331 | ||
| Patients' priorities in selecting chronic lymphocytic leukemia treatments | Q89777528 | ||
| Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL | Q33714712 | ||
| Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients | Q33821990 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells | Q35080394 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia | Q35868355 | ||
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| The B-cell receptor signaling pathway as a therapeutic target in CLL. | Q36163034 | ||
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36337598 | ||
| CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma | Q36470314 | ||
| BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia | Q36799197 | ||
| Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. | Q37148767 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials | Q38656503 | ||
| Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States | Q38792651 | ||
| Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies | Q38969861 | ||
| Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib | Q38974011 | ||
| Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia | Q39006397 | ||
| Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels | Q39025763 | ||
| Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). | Q39065374 | ||
| Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. | Q39217647 | ||
| Ibrutinib may impair serological responses to influenza vaccination | Q40154480 | ||
| High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation | Q42184742 | ||
| Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib | Q42318090 | ||
| Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. | Q42791753 | ||
| Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells | Q46055970 | ||
| ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia | Q46112511 | ||
| Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes | Q47136959 | ||
| Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy | Q47445525 | ||
| Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib | Q50044424 | ||
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis | Q50054062 | ||
| Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways | Q50065065 | ||
| P433 | issue | 21 | |
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| ibrutinib | Q5984881 | ||
| P304 | page(s) | 2249-2259 | |
| P577 | publication date | 2018-09-25 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia | |
| P478 | volume | 132 |
| Q93023511 | An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL |
| Q91303900 | Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on |
| Q91988095 | Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value |
| Q92671839 | Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine? |
| Q90307292 | Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment |
| Q89477099 | Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia |
| Q64086529 | Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL) |
| Q92630079 | Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk |
| Q93112998 | Reduced Dose Ibrutinib Due to Financial Toxicity in CLL |
| Q90429109 | The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice |
Search more.